Pathogen inactivation is a set of processes used to kill or neutralize viruses, bacteria and other infectious agents in biological materials such as blood products, plasma or cell therapies. Think of it like pasteurizing milk or disinfecting a surface: it reduces the risk that a product will transmit infection to a patient. For investors, this matters because effective pathogen inactivation can lower safety-related recalls and regulatory hurdles, support broader market access, and influence production costs and product pricing.
platelet componentsmedical
Platelet components are the portions of donated blood that contain platelets — tiny cells that help stop bleeding — separated and prepared for transfusion or medical use. Think of them as the ‘bandages’ in a blood bank: hospitals use them to treat patients with bleeding, low platelet counts, or during surgery, so their availability, shelf life and regulatory handling directly affect healthcare providers, blood centers and companies that supply or regulate blood products.
apheresis plateletsmedical
Apheresis platelets are platelets collected from a single donor using a machine that draws blood, separates and keeps the platelets, then returns the rest to the donor—like using a filter that takes only the needed part and gives the rest back. They matter to investors because they are a critical medical product with limited shelf life and specialized collection and storage needs, so supply, demand, regulation, and production costs can directly affect hospitals, blood-service providers, and companies in the medical supply chain.
cryoprecipitated fibrinogen complexmedical
Cryoprecipitated fibrinogen complex is a blood-derived product made by slowly thawing frozen plasma to concentrate clotting proteins, mainly fibrinogen, that help seal bleeding sites. Investors should care because it is used in hospitals for emergency bleeding and surgery, represents a regulated medical product with manufacturing and supply constraints, and can affect revenue and risk for companies involved in blood products or hospital supply chains.
amotosalenmedical
A synthetic chemical that, when activated by ultraviolet light, binds to and neutralizes viruses, bacteria and other infectious agents in donated blood and plasma to make transfusions safer. Investors care because products that use this technology affect the market for blood-safety equipment, regulatory approvals, hospital purchasing, and liability risk—much like a car’s safety airbag influences demand and regulatory scrutiny for auto makers.
uva inactivationmedical
UVA inactivation uses UVA (ultraviolet A) light to disable or kill microorganisms like viruses and bacteria by damaging their proteins and genetic material so they can’t reproduce. For investors, demonstrated UVA inactivation is important because it affects a product’s safety claims, regulatory clearance, market acceptance and competitive edge — much like proven filtration performance gives buyers confidence in a water purifier or air cleaner.
bacterial contaminationmedical
Bacterial contamination occurs when unwanted bacteria are present in products, manufacturing areas, medical devices, water, or raw materials, creating health risks, spoilage, or safety failures. Like a small leak that can corrode a ship’s hull, contamination can trigger recalls, production stoppages, regulatory fines, or reputational harm, all of which can quickly raise costs and reduce sales; investors track it because it can materially change a company’s risk profile and future earnings.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (Nasdaq: CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion (ISBT) 39th International ISBT Congress, taking place in Kuala Lumpur, Malaysia, from June 20 through June 24, 2026. Transfusion medicine experts and professionals from around the world are expected to attend the ISBT Congress.
“We look forward to highlighting how blood centers around the world are leveraging INTERCEPT technology to strengthen blood safety, improve operational efficiency and enhance patient care,” said Christian Boutemy, vice president, international commercial operations at Cerus. “This year’s abstracts reflect the growing body of evidence supporting the INTERCEPT Blood System, alongside valuable real-world experiences from blood centers across Asia. The presentations showcase innovations intended to help optimize operations, including reduced processing times with the LED-based INT200 illuminator and inventory management advantages associated with extended platelet shelf-life, as demonstrated by experience from Thailand. Importantly, an abstract from China draws attention to persistent bacterial contamination risks in platelet components and reinforces the value of a proactive pathogen-inactivation strategy in one of the world’s largest transfusion markets.”
The following is a list of selected presentations and abstracts of interest for Cerus. All presentation times are listed in Malaysian Time (MYT – UTC+8).
Oral Presentation
Sunday, June 21, 2026, 12:45–13:45 – Cerus symposium
Pathogen Inactivation: The Proactive Choice to Improve Blood Safety
Chair: Pimpun Kitpoka, Thailand
Presentations:
Blood safety - Miles to go, before we sleep – Dr. Albert Farrugia
INTERCEPT: Unmatched evidence and Proven patient benefits – Dr. Richard Benjamin
Poster Presentations
Poster-Session: Monday, June 22, 2026, 17:15–18:45 hours
Select Posters of Interest
P363 - Preserved Fibrinogen Recovery and Stability of Low Plasma Volume Pathogen Reduced Cryoprecipitated Fibrinogen Complex. M. Gatmaitan, A. Paez, Y. Luo et al
P373 - Reduction in Compound Adsorption Device Exposure Time for Pathogen Inactivated Platelet Components Treated With Amotosalen and an LED-Based Illumination Device. B. Dillon, A. Bernal, S. Crawford et al
P370 - Introduction of Pathogen-Reduced Double-Dose Apheresis Platelets in a Tertiary Teaching Hospital in Thailand – Impact on Component Characteristics and Clinical Use. S. Khuenkham, N. Neeranatpaiboon, M. Picard-Maureau et al
P376 - Amotosalen/UVA Inactivation of TTI-Associated Bacteria in Platelet Components. M. Krath, A. Engelhaupt, P. Nahata et al
P478 - Bacterial Contamination of Platelet Concentrates in China. H. Weidong, C. Yuanfeng, X. Junfeng et al
The full program of Cerus-related abstracts can be found here: https://interceptbloodsystem.com/wp-content/uploads/2026/06/2026_ISBT_AbstractBook.pdf.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
Cerus, INTERCEPT, and the Cerus logo are trademarks of Cerus Corporation.
